Endotheliopathy of trauma is an on-scene phenomenon, and is associated with multiple organ dysfunction syndrome:a prospective observational study by Naumann, David N et al.
 
 
Endotheliopathy of trauma is an on-scene
phenomenon, and is associated with multiple organ
dysfunction syndrome
Naumann, David; Hazeldine, Jon; Davies, David; Bishop, Jon; Midwinter, Mark; Belli, Antonio;
Harrison, Paul; Lord, Janet
DOI:
10.1097/SHK.0000000000000999
Document Version
Peer reviewed version
Citation for published version (Harvard):
Naumann, DN, Hazeldine, J, Davies, DJ, Bishop, J, Midwinter, MJ, Belli, A, Harrison, P & Lord, JM 2018,
'Endotheliopathy of trauma is an on-scene phenomenon, and is associated with multiple organ dysfunction
syndrome: a prospective observational study', Shock, vol. 49, no. 4, pp. 420-428.
https://doi.org/10.1097/SHK.0000000000000999
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 26/09/2017
Please note this is not the final version.
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
  
1 
Endotheliopathy of trauma is an on-scene phenomenon, and is 
associated with multiple organ dysfunction syndrome: 
a prospective observational study 
 
Running head: Prehospital endotheliopathy of trauma 
 
David N Naumann
1,2,3*
, Jon Hazeldine
2,3*
, David J Davies
3
, Jon Bishop
3
,  
Mark J Midwinter
4
, Antonio Belli
3
, Paul Harrison
2
, Janet M Lord
2 
 
 
1
Academic Department of Military Surgery and Trauma, Royal Centre for Defence Medicine, 
Queen Elizabeth Hospital, Birmingham, UK. 
2
Institute of Inflammation and Ageing, University of Birmingham Research Laboratories, 
Queen Elizabeth Hospital, Birmingham, UK. 
3
NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth 
Hospital, Birmingham, UK. 
4
University of Queensland, Rural Clinical School, Bundaberg, Queensland, Australia 
 
*DNN and JH have made an equal contribution, and share joint first authorship.  
 
Corresponding author (for both correspondence and reprints) 
Dr David N Naumann, Academic Department of Military Surgery and Trauma, Royal Centre 
for Defence Medicine, Queen Elizabeth Hospital, Birmingham, UK 
Email:  david.naumann@nhs.net 
Phone:  +44 (0) 7861 242 807 
 
Conflict of interest statement 
All authors declare that they have no competing interests. 
 
  
2 
Sources of funding  
Funding was provided by the National Institute for Health Research, and the Royal Centre for 
Defence Medicine. Although the corresponding author is affiliated to the UK Defence 
Medical Services, their opinions are their own, and do not necessarily represent those of the 
UK Defence Medical Services.  
  
  
3 
ABSTRACT 
 
Background 
Trauma patients are vulnerable to coagulopathy and inflammatory dysfunction associated 
with endotheliopathy of trauma (EoT). In vitro evidence has suggested that tranexamic acid 
(TXA) may ameliorate endotheliopathy. We aimed to investigate how soon after injury EoT 
occurs, its association with multiple organ dysfunction syndrome (MODS), and whether TXA 
ameliorates it. 
 
Methods 
A prospective observational study included 91 trauma patients enrolled within 60 minutes of 
injury and 19 healthy controls. Blood was sampled on enrolment and again 4–12 hours later. 
ELISAs measured serum concentrations of syndecan-1 and thrombomodulin as biomarkers of 
EoT. MODS was compared between groups according to biomarker dynamics: (a) 
persistently abnormal; (b) abnormal to normal; and (c) persistently normal. Timing of EoT 
was estimated by plotting biomarker data against time, and then fitting generalized additive 
models. Biomarker dynamics were compared between those who did or did not received 
prehospital TXA.  
 
Results 
Median age was 38 (IQR 24–55) years; 78/91 were male. Median injury severity score (ISS) 
was 22 (IQR 12–36). EoT was estimated to occur at 5–8 minutes after injury. There were no 
significant differences in ISS between those with or without prehospital EoT. 42 patients 
developed MODS; 31/42 with persistently abnormal; 8/42 with abnormal to normal; and 3/42 
with persistently normal biomarkers; p<0.05. There were no significant differences between 
TXA and non-TXA groups.  
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Conclusions 
EoT was present at the scene of injury. MODS was more likely when biomarkers of EoT 
were persistently raised. There were no significant differences between TXA and no TXA 
groups. Prehospital interventions aimed at endothelial restoration may represent a clinically 
meaningful target for prehospital resuscitation. 
 
Key words 
Endothelium; syndecan-1; glycocalyx; thrombomodulin; trauma; endotheliopathy; 
prehospital 
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INTRODUCTION 
 
Trauma induced coagulopathy (TIC) has been observed in injured patients on arrival in 
hospital(1), and within the prehospital environment(2, 3), suggesting that it may occur soon 
after injury. Abnormal inflammatory function following trauma has also been observed on 
admission to hospital(4), and we have recently reported that this occurs within the first hour 
following injury(5). Activation of the interconnected inflammatory and coagulation pathways 
are influenced by a “genomic storm” that occurs following injury, mimicking the response to 
critical inflammatory stress(6). This may include the disruption of the endothelial barrier, 
which has been proposed as a unifying mechanism for these processes following trauma(7). 
There have been no investigations of this specific process in the prehospital setting. Data 
regarding the timing and nature of endotheliopathy following injury and before arrival in 
hospital may facilitate a greater understanding of the mechanisms of coagulopathy and 
inflammatory disorder following trauma.  
 
The endothelial layer consists of endothelial cells, their basal lamina and the endothelial 
glycocalyx that lines the luminal surface. Endothelial injury and glycocalyx shedding may 
occur following trauma as a consequence of its exposure to circulating damage-associated 
molecular patterns (DAMPs)(8), neutrophil extracellular traps(9), sympathoadrenal 
activation(10), hypovolaemia(11), and ischemia(12). In injured patients, soluble 
thrombomodulin and syndecan-1 have been used as surrogate markers of endothelial cell 
injury and glycocalyx shedding respectively(10, 13). These biomarkers have been observed 
in abnormal concentrations in blood samples acquired from patients at hospital 
admission(13), but it is unknown exactly when endotheliopathy occurs following a traumatic 
insult. If endothelial activation and microcirculatory dysfunction are to be confirmed as a 
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unifying mechanism for the pathological inflammatory processes following trauma(7), then it 
would be expected that endotheliopathy precedes, or concurrently occurs, with coagulopathic 
and inflammatory changes following injury. We sought to investigate endotheliopathy of 
trauma (EoT) within a cohort of trauma patients that we recently observed to have early 
inflammatory and immune cell dysregulation(5).    
 
A recent in vitro study of the EoT demonstrated that when injured human umbilical vein 
endothelial cells were exposed to tranexamic acid (TXA), concentrations of both 
thrombomodulin and syndecan-1 (used as markers of endotheliopathy) were reduced 
significantly more than for those cells without TXA(14). This study generated the hypothesis 
that TXA may play some role in the amelioration of the EoT, but this has not been tested in 
the clinical setting.  
 
The current study measured biomarkers of endothelial cell injury (thrombomodulin) and 
glycocalyx shedding (syndecan-1) as surrogate markers of EoT. The aim of the study was to 
provide an estimation of the time of onset of EoT post-injury, and to investigate whether the 
evolution of EoT between the scene of injury and hospital admission is associated with 
subsequent organ failure. Furthermore, since these two time points represent “before” and 
“after” treatment with TXA, we tested the hypothesis that TXA might reduce biomarkers of 
EoT as has been reported in vitro(14).  
 
We hypothesised that there would be an early rise in biomarkers of EoT following trauma, 
which would be associated with poorer outcomes, and that patients who received TXA would 
have a greater decrease in biomarker levels than those who did not receive TXA.  
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METHODS 
 
Study design and setting 
A prospective longitudinal observational study was undertaken using a prehospital design 
described previously(5); trauma patients were enrolled during prehospital evacuation, as soon 
after injury as possible by paramedic personnel across a large UK major trauma network. 
After being conveyed to the regional Major (Level 1) Trauma Centre (University Hospitals 
Birmingham NHS Foundation Trust), study participants were followed up by embedded 
trauma research personnel. The current study includes patients from the Brain Biomarkers 
After Trauma Study (BBATS); Research Ethics Committee (REC) approval was granted 
prior to the start of the study (REC 5, Wales, Ref. 13/WA/0399). This study is reported 
according to the STROBE guidance for observational studies. Patients were enrolled from 
May 2014 to February 2017.  
Prehospital blood products were not available in this trauma network during the study 
period. Prehospital TXA delivery was given according to a specific protocol that included 
injured patients with any of the following: systolic blood pressure <90mmHg; heart rate 
>100bpm; risk of significant haemorrhage; or who required intravenous fluid therapy. 
Patients were not given TXA if more than 3 hours had passed since injury, if they had an 
isolated head injury, a known history of convulsions, or hypersensitivity to TXA.      
 
Study participants 
Trauma patients with the likelihood of an Injury Severity Score (ISS) of 8 or higher were 
eligible for inclusion, regardless of type of injury. Since ISS is not usually calculated until 
after the patient has left hospital, specific training was delivered to the prehospital 
practitioners within the study region before the start of the study, so that prediction of likely 
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ISS could be made as appropriate. Patients were excluded if they were pregnant, prisoners, or 
under the age of 16. Patients could only be enrolled if there was a peripheral venous sample 
of blood taken within 60 minutes from time of injury. All eligible patients were screened by 
dedicated research staff on arrival in ED to minimise the risk of selection bias. For the 
purposes of the current study, patients with isolated traumatic brain injury were excluded.  
 
Capacity and consent 
Due to the injuries sustained and requirement for swift emergency evacuation, it was 
considered that patients would not have capacity to consent. The REC-approved protocol was 
undertaken according to the World Medical Association Declaration of Helsinki, and the 
Mental Capacity Act 2005. In brief, a close relative or friend (Personal Consultee) was asked 
to assent for the patient’s participation in the study, based on their prior knowledge of the 
participant’s wishes. Once the patient regained capacity, they were approached in order to 
gain consent for the retention of data already obtained, and for continued follow up. If a 
patient did not regain capacity, the permission from their Personal Consultee to participate in 
the study remained extant.  
 
Blood sampling and storage 
Peripheral blood samples were taken during the prehospital evacuation of all patients within 
60 minutes of injury. The timing of this sample was meticulously recorded in 
contemporaneous records by prehospital personnel (designated as the “prehospital” time 
point). A further peripheral blood sample was taken between 4 and 12 hours after injury 
(designated the “in-hospital” time point). Blood samples were collected into BD 
Vacutainers
®
 (Becton Dickinson, Oxford, UK) containing z-serum clotting activator. 
Following a 30-minute incubation at room temperature, samples were centrifuged at 4
o
C for 
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10 minutes at 1,620 x g. Aliquots were stored at -80
o
C until analysed. Serum samples were 
acquired and stored for 19 “healthy control” (HC) volunteers, who were matched as a group 
for sex and age to the study cohort. All HCs had declared themselves to be in good health, 
and not currently under any medical investigations or treatment, and had no chronic diseases.   
 
Enzyme-linked immunosorbent assays 
Commercially available ELISAs were used to detect concentrations of syndecan-1 (CD 138) 
(Abcam, ab46506, Cambridge, MA) and thrombomodulin (CD 141) (Abcam, ab46508, 
Cambridge, MA) in the serum samples. Analysis was undertaken in accordance with the 
relevant protocols, including the use of control and blank wells in order to validate the 
results.  
 
Data collection 
Data was recorded prospectively for all patients, and then confirmed using electronic and 
paper records. Data included patient demographics (age, gender), and mechanism of injury. 
Injury severity scores (ISS) were acquired from the centralised UK Trauma Audit and 
Research Network after discharge from hospital. Physiological parameters in ED included 
lowest systolic blood pressure and associated heart rate, and Glasgow Coma Scale. Serum 
lactate and base deficit in ED were also recorded. Timings of blood samples were collected 
contemporaneously by prehospital practitioners. Delivery of TXA between the first and 
second time points was recorded in order to dichotomise patients into those who had received 
TXA and those who had not.  
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Outcomes 
The primary outcome for this study was development of multiple organ dysfunction 
syndrome (MODS), defined as a sequential organ failure assessment (SOFA) score of 6 or 
higher on 2 or more consecutive days during their admission in hospital after the first 48h 
following injury(4, 5). Mortality within 90 days was also recorded for all patients.   
 
Data analysis 
A Shapiro-Wilk test was used to determine the normality of continuous data. Non-normal 
data are presented as median and interquartile range (IQR). Syndecan-1 and thrombomodulin 
concentrations were considered abnormal if they were above the 97.5
th
 percentile of HC 
levels; patients were considered to have endotheliopathy if they had abnormal values for 
either biomarker (syndecan-1, thrombomodulin, or both). Correlation between non-normal 
continuous variables was undertaken using Spearman’s rank correlation coefficient. Non-
normal continuous data were compared between groups using a Kruskal-Wallis test, followed 
by pairwise comparisons between groups using Dunn’s multiple comparisons test. 
Categorical data were compared using Fisher’s exact test for pairwise comparisons, and chi-
squared analysis for trends between groups, and reported as n/denominator. A p-value of 
<0.05 was considered significant. Where appropriate, further designation of significance was 
made by indicating when p-values were <0.01, <0.001 and <0.0001. 
 
a. Estimation of the time of onset of endotheliopathy 
It is highly unlikely that any study of humans will be able to determine the concentrations of 
biomarkers at the point of wounding, and therefore statistical modelling was considered the 
best opportunity to estimate the timing of biomarkers following injury. In order to determine 
the most likely time at which endothelial injury and glycocalyx shedding occur following 
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injury, the concentrations of thrombomodulin and syndecan-1 for all patients were plotted 
against time from injury. Syndecan-1 and thrombomodulin concentrations derived from HCs 
were plotted at the origin, on the assumption that trauma patients would have been within the 
same range prior to injury. Analysis was then performed by fitting generalized additive 
models to the data using penalized regression splines with smoothing parameters selected by 
residual maximum likelihood. This modelling approach accounts for the distinctly non-linear 
pattern of the data that cannot be adequately modelled with standard parametric regression 
approaches. For each biomarker, two curves were plotted: the group of “abnormal” values 
(higher than the 97.5
th
 percentile of HCs) and the group of “normal” values which were 
between the 2.5
th
 and 97.5
th
 percentiles of HCs. The point at which the abnormal curve 
crossed the line of significance was considered to be an estimation for the point at which 
endotheliopathy occurred following injury.  
 
b. Measuring the effects of TXA 
Patients who had prehospital endotheliopathy were dichotomised into those who received 
TXA within the prehospital period (between time points) and those that did not. Biomarkers 
were then compared before and after treatment in order to determine whether there were any 
differences between the two groups. 
 
c. Investigating the association between endotheliopathy and MODS  
Patients with both pre- and in-hospital serum samples were categorised according to their 
biomarkers over the two time points: (a) those with persistent abnormal biomarkers; (b) those 
that had abnormal biomarkers that reduced to normal range; and (c) those with normal 
biomarkers throughout. The numbers of patients who developed MODS were compared 
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between these three groups. Furthermore, individual biomarkers were compared between 
those who developed MODS and those who did not.  
 
 
 
RESULTS  
 
Study participation 
A total of 816 patients were screened for eligibility during the study period, of which 107 
were potentially eligible patients who had blood samples taken within 60 minutes of injury. 
After 16 were excluded due to isolated traumatic brain injury, there were 91 patients 
included. The median time of blood sampling for the prehospital time point was 45 (IQR 33–
55) minutes after injury. The median time of blood sampling for the second (in-hospital) time 
point was 5.5h (IQR 4.2h – 10.5h).  
Enrolment and participation at each stage are illustrated in a flow diagram (Figure 1), 
with asterisks to indicate which denominator is used for each stage of data analysis. The 
prehospital blood samples were insufficient for analysis for 3 patients, and the in-hospital 
blood samples were insufficient for a further 9 patients, so that 79/91 patients had both pre- 
and in-hospital samples suitable for analysis. The denominators used for the different 
analyses differ accordingly: 
(a) Analysis of the timing of EoT after injury: N=88 (all prehospital samples) 
(b) Comparison of biomarkers according to outcomes (MODS and mortality); and 
comparison between TXA and non-TXA: N=91 (all patients).  
(c) Comparison of patient groups according to dynamic changes in endotheliopathy between 
pre- and in-hospital time points: N=79 (all patients with both pre- and in-hospital 
samples)  
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Patient characteristics 
The median age of all patients was 38 (IQR 24–55) years, and 78/91 were male. Patient 
characteristics are illustrated in Table 1, with comparison between patients with prehospital 
EoT and those without. There was a higher proportion of patients with blunt injury in the 
prehospital endotheliopathy group than those without prehospital endotheliopathy (60/71 
versus 9/17; p<0.01). All other characteristics were not significantly different between the 
groups. 
 
 
Table 1. Study participant characteristics according to presence of endotheliopathy at the 
prehospital time point 
 
Patient characteristic 
All 
(N=88) 
Prehospital 
Endotheliopathy 
(N=71) 
No prehospital 
endotheliopathy 
(N=17) 
 
 
p-value 
Age, years 33 (24–53) 38 (24–56) 25 (23 – 44) 0.343 
Sex, male 75 (85) 61 (86) 14 (82) 0.993 
Mechanism of injury     
         Blunt 69 (78) 60 (85) 9 (53) 0.008* 
         Penetrating 19 (22) 11 (15) 8 (47)  
Injury Severity Score 23 (12–36) 24 (14–36) 16 (9–29) 0.267 
Physiological parameters in ED      
         Lowest SBP, mmHg 115 (99–124) 114 (99–124) 119 (102–124) 0.666 
         Heart rate, min
-1
 88 (76–99) 87 (75–99) 89 (78–103) 0.629 
         Glasgow Coma Scale 13 (5–15) 13 (4–15) 15 (10–15) 0.150 
         Serum lactate, mmol/l 4.1 (2.5–6.5) 4.2 (2.7–6.7) 3.5 (2.0–5.5) 0.259 
         Base deficit, mmol/l -3 (-6 – -1) -3 (-6 – -1) -3 (-6 – -1) 0.438 
Summary data are presented as median (interquartile range); categorical data are reported as N (%)  
ED: Emergency Department; SBP: systolic blood pressure 
*Significant according to Fisher’s exact test 
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Presence of endotheliopathy 
According to serum concentrations of thrombomodulin and syndecan-1 for HCs and patients, 
there was a significant difference between them at both time points, for both biomarkers, as 
illustrated in Table 2. According to the presence of abnormal syndecan-1 or thrombomodulin 
concentrations, prehospital and in-hospital endotheliopathy were present in 71/88 (81%) and 
51/82 (62%) patients respectively. For patients with samples available at both time points 
(N=79) (Figure 1), 50/79 had persistently abnormal biomarkers, 18/79 had abnormal 
biomarkers that returned to normal, and 11/79 had normal biomarkers throughout; their 
characteristics are illustrated in Table 3. There was a significant difference across groups for 
serum lactate, base deficit, and SBP (all p<0.05). Of all patients with biomarkers at both time 
points, there were 20/79 (25%) who received blood products between the time points. There 
was a significant difference in transfusion requirement between these groups according to 
biomarker dynamics; almost all of those requiring transfusion were in the group that had 
persistently abnormal biomarkers (p < 0.01) (Table 3).      
 
 
Table 2. Serum syndecan-1 and thrombomodulin concentrations for healthy controls and 
patients according to time point.  
 
Biomarker, ng/ml 
Healthy controls 
(N=19) 
Prehospital 
(N=88) 
In-hospital 
(N=82) 
Syndecan-1 30 (20–44) 59 (39 – 140)*** 53 (28 – 150)* 
Thrombomodulin 2.9 (2.2 – 3.4) 4.9 (3.8 – 6.4)*** 4 (3.4 – 5.1)** 
Data are presented as median (interquartile range), ng/ml 
*p<0.01, **p<0.001, and ***p<0.0001 when compared to healthy controls using Dunn’s multiple comparisons 
test  
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Table 3. Patient characteristics according to change in serum syndecan-1 and 
thrombomodulin concentrations between the prehospital and in-hospital time points 
 
Patient characteristic 
 
Abnormal-
abnormal 
(N=50) 
 
Abnormal-
normal 
(N=18) 
 
Normal-
normal 
(N=11) 
 
 
p-value 
Age, years 39 (25–63) 36 (24–45) 25 (23–48) 0.417 
Sex, male 42 (84) 16 (89) 9 (82) 0.974 
Mechanism of injury     
         Blunt 39 (78) 17 (94) 7 (64) 0.729 
         Penetrating 11 (22) 1 (6) 4 (36)  
Injury Severity Score 25 (15–38) 29 (16–38) 17 (9–29) 0.230 
Physiological parameters in ED      
         Lowest SBP, mmHg 113 (95–122) 119 (105–129) 122 (106–134) 0.030* 
         Heart rate, min
-1
 87 (80–99) 93 (81–104) 88 (76–104) 0.627 
         Glasgow Coma Scale 13 (3–14) 12 (6–14) 15 (11–15) 0.083 
         Serum lactate, mmol/l 4.8 (3.0–7.2) 3.7 (2.5–6.4) 2.4 (1.3–4.6) 0.037* 
         Base deficit, mmol/l -4 (-8 – -2) -3 (-6 – -1) -2 (-3 – 0) 0.023* 
Blood product requirement     
         All patients transfused 19 (38) 0 (0) 1 (10) 0.003** 
         Patients given RBCs 19 (38) 0 (0) 1 (10) 0.003** 
         Patients given FFP 12 (24) 0 (0) 0 (0) 0.017** 
Summary data are presented as median (interquartile range); categorical data are reported as N (%)  
ED: Emergency Department; SBP: systolic blood pressure; RBC: red blood cells; FFP: fresh frozen plasma 
*Significant according to Kruskal-Wallis test 
**Significant according to Chi-squared test 
 
 
Endotheliopathy occurs within minutes of injury 
There was evidence of glycocalyx shedding and endothelial cell damage within the 
prehospital (<60 min) phase amongst this cohort of patients. Before statistical modelling, the 
first recorded abnormal syndecan-1 and thrombomodulin concentrations amongst the patient 
cohort were observed at 17 and 18 minutes following injury respectively (Figure 2).  When 
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the statistical model was used, glycocalyx shedding and endothelial cell injury were 
estimated to occur at approximately 5 and 8 minutes following injury respectively (Figure 2).   
 
Endotheliopathy is associated with poor perfusion 
When prehospital and in-hospital concentrations of syndecan-1 and thrombomodulin were 
compared to the serum lactate during ED resuscitation (as a surrogate marker of 
microcirculatory perfusion), there was a significant correlation with both prehospital and in-
hospital syndecan-1 (Figures 3a and 3b respectively), and in-hospital thrombomodulin 
(Figure 3d); all p<0.05. However, there was no significant correlation between lactate and 
prehospital thrombomodulin concentration (Figure 3c).     
 
Endotheliopathy is associated with MODS 
Figure 4 illustrates the biomarker levels of patients according to whether they developed 
MODS. When patients who developed MODS were compared to those without MODS, the 
former had significantly higher syndecan-1 concentrations at the prehospital (91 (IQR 48–
184) ng/ml vs 47 (IQR 33–109) ng/ml; p<0.05) and in-hospital (64 (IQR 42–199) ng/ml vs 38 
(IQR 25–98) ng/ml; p<0.01) time points. For patients with MODS, the pre- and in-hospital 
biomarker levels were both significantly higher than those of HCs (30 (IQR 19–44) ng/ml); 
p<0.0001 and p<0.001 respectively. Patients without MODS also had significantly higher 
syndecan-1 concentrations in the prehospital samples (p<0.05) but not in the in-hospital 
samples (p=0.216) (Figure 4a). 
Patients with MODS had significantly higher thrombomodulin concentrations at the 
prehospital (5.4 (IQR 4.0–7.1) ng/ml vs 4.5 (IQR 3.4–5.9) ng/ml; p<0.05) and in-hospital (4.5 
(IQR 3.6–5.5) ng/ml vs 3.6 (IQR 2.9–4.5) ng/ml; p<0.01) time points. For patients with 
MODS, the pre- and in-hospital biomarker levels were both significantly higher than those of 
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HCs (2.9 (IQR 2.2–3.5) ng/ml); p<0.0001 for both. Patients without MODS had significantly 
higher thrombomodulin concentrations in the prehospital samples (p<0.0001) but not in the 
in-hospital samples (p=0.065) (Figure 4b) 
 
Changes in biomarkers are associated with MODS  
For those patients with both prehospital and in-hospital samples (n=79), 42/79 patients 
developed MODS. These included 31/42 who had persistently abnormal biomarkers, 8/42 
had abnormal prehospital biomarkers that normalised, and 3/42 had normal biomarkers at 
both time points; p<0.05.  
When patients were compared according to dynamic change in biomarkers, MODS 
developed in 31/50 in the group that had persistently abnormal biomarkers, 8/18 in the group 
that had abnormal biomarkers that returned to normal range, and 3/11 in the group that had 
normal biomarkers throughout; p < 0.05 (Figure 5a). When syndecan-1 and thrombomodulin 
were examined separately, there was a similarly significant trend for MODS according to 
both biomarkers; p<0.05 and p<0.01 respectively (Supplementary Figure 1). 
There were 12 patients who died. There was no significant difference in mortality 
within groups according to dynamic changes in biomarkers; 9/50 with persistently abnormal 
biomarkers, 2/18 of those with abnormal biomarkers that returned to normal range, and 1/11 
of those with normal biomarkers throughout died; p = 0.652 (Figure 5b).  
 
TXA did not influence biomarkers of endotheliopathy  
Of all patients, there were 55/91 who received prehospital TXA, 35/91 did not, and one 
patient was randomized to either TXA or placebo as part of the CRASH-3 study(15). There 
were 38 patients with abnormal prehospital syndecan-1, of which 23/38 received TXA. There 
were no differences in syndecan-1 concentration at either time point according to TXA group 
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(Figure 6a). There were 43 patients with abnormal prehospital thrombomodulin, of which 
25/43 received TXA. There were similarly no differences in thrombomodulin concentrations 
at either time point according to TXA group (Figure 6b).   
 
 
DISCUSSION 
The main finding of this study is that trauma-induced endotheliopathy occurred within 
minutes of injury, and failure of abnormal biomarkers to return to normal was associated with 
a higher burden of organ dysfunction. MODS was associated with higher syndecan-1 and 
thrombomodulin at both prehospital and in-hospital time points, but there was no association 
between delivery of TXA and biomarker levels. Endotheliopathy is likely to occur rapidly 
following injury, with observed biomarker levels raised at 17 minutes within the patient 
cohort, and statistical modeling of data predicting that this occurs within 5 – 8 minutes of 
injury. These data are in keeping with the hypothesis that endotheliopathy is a common 
mechanism(7, 16), and may partly explain why phenomena such as TIC and inflammation 
have been recorded in the prehospital environment and on arrival of patients in hospital. 
These data are also in keeping with previous evidence that high syndecan-1 is associated with 
poorer outcomes amongst trauma patients, even when taken very early after patient admission 
to hospital(17).   
 
Our observations of early endotheliopathy following injury are in keeping with the current 
understanding of the mechanisms of early coagulopathy, since glycocalyx shedding and 
endothelial cell injury stimulate the generation of thrombin and activation of protein-C, with 
subsequent hyperfibrinolysis(18). Since inflammatory derangement following cellular injury 
may also be associated with subsequent sepsis(19) and organ failure(4), early reversal of 
these interconnected processes has the potential to improve outcomes. The patients that 
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developed MODS in this study came from the same cohort that showed inflammatory and 
immune cell dysregulation in our previous detailed study of immune function, with raised 
levels of IL-6, IL-8, and TNFa at both prehospital and in-hospital time points when compared 
to healthy controls(5). Together, these data support the hypothesis that there is an early and 
important relationship between endothelial injury and altered immune function following 
trauma, and that these derangements occur within minutes of injury. Multiple studies have 
reported independent associations between high injury severity, high plasma adrenalin level, 
and high circulating syndecan-1 and thrombomodulin levels, suggesting that sympatho-
adrenal hyper-activation following shock may be a key driving factor in this process(5).  
 
During the resuscitation of critically unwell trauma patients, lactate has been shown to be a 
useful biomarker of perfusion as a one-off reading and also in terms of progression between 
values (as lactate clearance),(20). In a similar manner, we present one-off individual 
biomarkers of endotheliopathy, but also progression of biomarkers during resuscitation, 
where the normalization of biomarkers are taken as a surrogate marker of endothelial 
restoration. In the current study, MODS was associated with non-reversal of endotheliopathy, 
and less common amongst those with endothelial biomarkers that returned to normal range. 
Restoration of the injured endothelium may therefore represent a meaningful clinical target 
for goal directed therapy during prehospital evacuation. Deliberate targeting of endothelial 
integrity is not currently undertaken in clinical practice. Plasma-based fluid resuscitation 
represents one possible treatment of choice for patients in this context, since both 
preclinical(21) and clinical(22) investigations have reported restoration of the endothelial 
glycocalyx after its delivery. The current study was non-randomized, and patients who had 
received plasma were more likely to be in the group that had persistently abnormal 
biomarkers. Although there were no significant differences in ISS between groups, a greater 
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requirement for blood product transfusion in this group suggests a higher number of patients 
with hemorrhagic trauma. A similar selection bias has been reported in observational studies 
of prehospital blood products, limiting meaningful clinical interpretation(23). These data 
cannot therefore be used to determine the efficacy of plasma-based resuscitation in the 
mitigation of endotheliopathy of trauma; further clinical investigations are required to test the 
hypothesis that plasma may allow endothelial restoration, especially if randomized controlled 
trials of prehospital plasma-based fluid resuscitation report improved clinical outcomes.   
 
The need for prehospital research has been emphasised by the World Health Organisation(24) 
and the Institute of Medicine of the National Academies(25), and may enable questions to be 
addressed that are not necessarily answered by preclinical studies(26). Although the old 
concept of the “golden hour” may not have as much of a bearing on outcomes as it was first 
supposed(27), it appears to represent a time during which a cascade of important pathological 
processes occur following injury, very close to the point of wounding. The data from this 
study have been obtained within the prehospital period, within the first hour following injury. 
Rather than waiting until arrival in hospital to attempt to address pathological processes, 
there may be some justification for working towards earlier, and more bespoke, intervention 
for critically unwell patients(28). Such an approach has already been advocated in terms of 
remote damage control resuscitation(29), and the consideration of the endothelium and blood 
together as an “organ” during resuscitation following trauma(30).       
 
The derangement of fibrinolysis has been considered as a target for trauma resuscitation in 
bleeding patients, such as with tranexamic acid(31) and fibrinogen concentrate(32), but there 
are no clinical therapies directly targeting the restoration of the glycocalyx or endothelial 
integrity. We were unable to confirm recent in vitro findings that early delivery of TXA can 
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reduce the burden of endotheliopathy following injury(14, 33). This may be due to the 
observational study design, and the heterogeneity in patient injury patterns and severity, as 
shown by the large confidence intervals in the data. Further investigation may be warranted 
on a larger scale, with a more homogenous population, using randomization to reduce the risk 
of selection bias.  
 
More than half of patients who did not reverse their endotheliopathy went on to develop 
multiple organ failure. Although causality cannot be demonstrated in the current study, the 
relationship is in keeping with previous descriptions of early inflammatory dysfunction and 
MODS(4, 5). The reason that some patients have biomarkers that are restored to normal 
range but others do not (or indeed why some have normal biomarkers throughout) is 
unknown, and was not related to ISS within this study cohort. There was evidence that serum 
lactate, base deficit and SBP were significantly different between these groups which may 
imply that the degree of shock and perfusion are related to endothelial integrity – a finding 
supported by the relationship between biomarkers and serum lactate in our study. It is notable 
that although this association was statistically significant, the correlation was not perfect, 
suggesting that there is a complex relationship between perfusion and endothelial integrity, 
with other confounding factors in a heterogeneous trauma population. Further mechanistic 
studies are required to investigate the precise relationships between the endothelium, 
perfusion, and subsequent organ function following trauma.   
 
It is likely that there are some genetic factors in the ability of the endothelium to respond to 
trauma and resuscitation, and early biomarkers may be one way of detecting these 
predispositions. Other biomarkers in trauma have been proposed as prognostic indicators(34), 
but these are not commonly used for trauma triage or goal directed therapy in clinical 
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practice. The utilization of such biomarkers—including those that may indicate 
endotheliopathy—remains a tantalizing potential avenue for future trials. If strategies to treat 
the endothelium are planned in the future, it seems that early treatment (within the prehospital 
environment) would be warranted since the current study suggests that early reversal (within 
12 hours) is associated with lower morbidity.    
 
Limitations 
The current study is limited by its number of patients when analyzing differences in relatively 
rare occurrences such as mortality; although there appears to be a non-survival trend in the 
same direction as MODS, this was not found to be statistically significant. Not all patients 
had samples available from both time points. These patients were excluded during subgroup 
analysis, which gives potential risk of selection bias. The style of opportunistic study 
enrolment during prehospital evacuation makes the study at risk of selection bias, since only 
a proportion of eligible patients were recruited into the study. This risk was reduced by the 
maintenance of a screening log to ensure that “missed” patients were not significantly 
different in demographics and injury patterns than included patients.  
 The statistical modeling performed to evaluate the timing of endotheliopathy should 
be considered as an estimation only, since it requires several assumptions that have the 
potential to be biased; it was assumed that patients had similar biomarkers to HCs prior to 
injury, and that biomarker levels above the 97.5
th
 percentile of HCs represented the 
development of endotheliopathy. These assumptions were required for a pragmatic 
estimation, since time-of-injury sampling is unlikely to be ethically justifiable or logistically 
realized. 
 The reliability of out-of-hospital blood samples has been questioned in simulations of 
“prehospital” delay(35), which has the potential to bias results based on time difference 
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between sampling and arrival hospital. Since this was a pragmatic, real-life study, such a risk 
may exist, but was kept to a minimum by maintaining strict and consistent preparation 
techniques as soon as the sample was received.  
 
We report that endothelial cell injury and glycocalyx shedding were observed within minutes 
following injury, and that statistical modeling predicted that this may occur at approximately 
5–8 minutes. Failure to reverse prehospital endotheliopathy is associated with poorer clinical 
outcome in terms of multiple organ dysfunction syndrome. Biomarker dynamics did not 
appear to be related to injury severity. In our non-randomized study, TXA was not associated 
with reduced levels of biomarkers of endotheliopathy. These findings, together with other 
reports of early coagulopathy and inflammatory dysregulation, suggest that early 
interventions aimed at restoration of the endothelium may represent a clinically meaningful 
target for resuscitation. The most appropriate treatment for this purpose in the clinical context 
remains uncertain.    
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Figure 1. Flow diagram of patient enrolment and participation at each stage of analysis.  
The denominators for analysis are: *N=91 for analysis of biomarkers according to multiple 
organ dysfunction syndrome (MODS) and mortality, and comparison of tranexamic acid 
(TXA) and non-TXA; **N=88 for analysis of timing of endotheliopathy; and ***N=79 for 
analysis of dynamic changes in endotheliopathy between time points 
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Figure 2. Concentrations of (a) syndecan-1 and (b) thrombomodulin in relation to time 
of injury.  
Healthy controls are plotted at time = 0 min. Patients are divided into those with elevated 
concentrations of the biomarker (>97.5
th
 percentile of healthy controls), and those with 
normal concentrations (2.5
th
 – 97.5th percentiles of healthy controls). For each curve the 
central trend line represents the average values, with the upper and lower trend lines 
representing the 2.5
th
 and 97.5
th
 percentiles of observed values. The vertical interrupted red 
line indicates the time at which biomarkers are likely to be first elevated.  
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Figure 3. Concentrations of Syndecan-1 and thrombomodulin in relation to lactate 
concentration during ED resuscitation; including (a) prehospital syndecan-1; (b) in-
hospital syndecan-1; (c) prehospital thrombomodulin; and (d) in-hospital 
thrombomodulin.  
Blue dashed lines represent 95% confidence intervals.  
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Figure 4. Concentrations of (a) syndecan-1 and (b) thrombomodulin according to time 
point and development of multiple organ dysfunction syndrome (MODS).  
Healthy controls (HC) are displayed for comparison.  
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs HCs 
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Figure 5. Presence of (a) multiple organ dysfunction syndrome (MODS) and (b) 90-day 
mortality amongst patients according to dynamic changes in levels of both syndecan-1 
and thrombomodulin between prehospital and in-hospital time points.  
Significance is indicated according to 2 test for trend. 
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Figure 6. Prehospital and in-hospital levels of syndecan-1 and thrombomodulin 
according to whether TXA was given to the patient during the prehospital period.  
Vertical bars represent 95% confidence intervals around the median.  
 
 
 
 
 
 
 
Supplementary Figure 1. Presence of multiple organ dysfunction syndrome (MODS) 
according to dynamic changes in individual biomarker levels (a) syndecan-1 and (b) 
thrombomodulin between prehospital and in-hospital time points.  
Significance is indicated according 2 test for trend.  
 
